DXCM241101P74000
- 4.50
- +1.25+38.46%
DexCom Newsroom
J.P. Morgan Downgrades DexCom(DXCM.US) to Hold Rating, Cuts Target Price to $85
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $85 to $115
J.P. Morgan Sticks to Its Hold Rating for Dexcom (DXCM)
DexCom Price Target Cut to $99.00/Share From $115.00 by Raymond James
DexCom Is Maintained at Neutral by JP Morgan
Dexcom's Strategic Resilience and Growth Prospects Support Buy Rating
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $75 to $120
DexCom Analyst Ratings
Dexcom (DXCM) Gets a Buy From Stifel Nicolaus
Wells Fargo Keeps Their Buy Rating on Dexcom (DXCM)
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)
Optimistic Outlook and Strategic Advancements Justify Buy Rating for Dexcom
Piper Sandler Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Dexcom (DXCM) Receives a Buy From Piper Sandler
DexCom Is Maintained at Outperform by RBC Capital
DexCom Analyst Ratings
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $120
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $89
Piper Sandler Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $80